Optimising screening for early disease detection in familial pulmonary fibrosis

Recruiting

• Conditions: familial lung fibrosis; familial pulmonary fibrosis; 10038686; 10024967

• Registration Number: NL-OMON51138
• Lead Sponsor: Sint Antonius Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 200

Inclusion Criteria

Subjects must be a first-degree relative of a patient with familial pulmonary
fibrosis
Subjects are reffered by a medical doctor for screening of familial pulmonary
fibrosis

Exclusion Criteria

- A previous diagnosis of an interstitial lung disease (ILD)
- Pregnancy

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Presence of Interstitial Lung Disease (ILD) changes on HRCT are indicative of<br /><br>preclinical interstitial lung disease and will be determined at baseline.<br /><br>Putative parameters of early lung disease that will be investigated include<br /><br>lung function, exercise tests, blood based biomarkers, MUC5B rs35705950<br /><br>genotype, physical examination for digital clubbing and crackles, and<br /><br>self-reported cough and dyspnoea.<br /><br>The primary endpoint is the difference in these parameters between the group<br /><br>with ILD changes on HRCT as compared to the group without ILD changes on HRCT.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>The secondary endpoints are differences in values for parameters between the<br /><br>baseline and follow-up screening after one and two years for the ILD changes<br /><br>and no ILD changes cohort and differences between these groups. </p><br>